Understanding micrometastatic disease and Anoikis resistance in ewing family of tumors and osteosarcoma.
about
Anoikis resistance: an essential prerequisite for tumor metastasisB7-H3 is overexpressed in patients suffering osteosarcoma and associated with tumor aggressiveness and metastasis.Zoledronic acid inhibits pulmonary metastasis dissemination in a preclinical model of Ewing's sarcoma via inhibition of cell migration.3D tissue-engineered model of Ewing's sarcomaCombination immunotherapy with α-CTLA-4 and α-PD-L1 antibody blockade prevents immune escape and leads to complete control of metastatic osteosarcoma3-bromopyruvate and buthionine sulfoximine effectively kill anoikis-resistant hepatocellular carcinoma cells.The histone deacetylase inhibitor, MS-275 (entinostat), downregulates c-FLIP, sensitizes osteosarcoma cells to FasL, and induces the regression of osteosarcoma lung metastases.RanBP9/TSSC3 complex cooperates to suppress anoikis resistance and metastasis via inhibiting Src-mediated Akt signaling in osteosarcomaCD99 triggering induces methuosis of Ewing sarcoma cells through IGF-1R/RAS/Rac1 signaling.Interference with Tim-3 protein expression attenuates the invasion of clear cell renal cell carcinoma and aggravates anoikis.Safety considerations for transplanting cryopreserved ovarian tissue to restore fertility in female patients who have recovered from Ewing's sarcoma.Significance of MTA1 in the molecular characterization of osteosarcoma.Overexpression of pyruvate kinase M2 predicts a poor prognosis for patients with osteosarcoma.Inhibition of IL-18-mediated myeloid derived suppressor cell accumulation enhances anti-PD1 efficacy against osteosarcoma cancer.Sarcoma Spheroids and Organoids-Promising Tools in the Era of Personalized Medicine.Local release of gemcitabine via in situ UV-crosslinked lipid-strengthened hydrogel for inhibiting osteosarcoma
P2860
Q28397372-D9D55951-CBC4-4778-83A4-0A045512F81AQ34935785-9F001CF2-14A7-4E57-8DCD-C5564DD94BD7Q35115510-A5AD1299-32CA-4563-A471-F38C4BE50FB7Q35428655-A8E009B3-CC3B-4B62-BB79-D000ECCD6A27Q35624496-4177E156-5A23-41E7-B618-A0E8B1A3A00EQ36330235-FBE0878E-F450-46EB-BE26-F6BDD8E27319Q37427549-31130399-DFA5-4550-AEB7-7903B72BC0C7Q37603522-AE16948C-0829-4E97-8778-CC057CE2D045Q37694869-3597DB42-4E83-452B-89E4-F3DD201F0201Q37722095-9FEBBD5A-618C-404D-B25C-030536213D0AQ38184581-64B46085-6FC1-4497-A434-F09A1A7A9DDEQ38260257-5945E1C4-D7B2-4FA4-B9A5-632AC76F6676Q39374497-BBB3F6CB-C0DA-4E75-A48E-3229304BFFD3Q47113668-7B53ECE9-D927-4C2C-96C0-1149B2A1B2B2Q50868047-305ACC4E-C2FD-4D5D-8041-338E847F37E2Q58700964-3A6BF025-8387-42B1-BE48-03DE1F2A4BB3
P2860
Understanding micrometastatic disease and Anoikis resistance in ewing family of tumors and osteosarcoma.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Understanding micrometastatic ...... ly of tumors and osteosarcoma.
@ast
Understanding micrometastatic ...... ly of tumors and osteosarcoma.
@en
type
label
Understanding micrometastatic ...... ly of tumors and osteosarcoma.
@ast
Understanding micrometastatic ...... ly of tumors and osteosarcoma.
@en
prefLabel
Understanding micrometastatic ...... ly of tumors and osteosarcoma.
@ast
Understanding micrometastatic ...... ly of tumors and osteosarcoma.
@en
P2093
P2860
P1433
P1476
Understanding micrometastatic ...... ly of tumors and osteosarcoma.
@en
P2093
Ariadna Mendoza-Naranjo
Jeremy Whelan
Poul H B Sorensen
Sandra J Strauss
P2860
P304
P356
10.1634/THEONCOLOGIST.2010-0093
P577
2010-05-17T00:00:00Z